Aptahem to start toxicology programme for Apta-1
Aptahem AB (publ.), a biotech company that develops aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation interact in the disease process, can today announce that it will start its first toxicology trials this week.
Aptahem has reached a milestone in its development programme for Apta-1 with the start of preliminary toxicology trials later this week. The non-GLP (Good Laboratory Practice) trials, will include dose range finding (DRF) studies in two different animal types to drive the programme faster forward. The trials seek to identify appropriate dose levels prior to the regulatorily important GLP trials that are compulsory prior to clinical trials.
“We´re delighted with the progress that we have made in the development of the unique drug candidate that Apta-1 represents, and we´re looking forward to seeing the results of these initial toxicology trials as soon as they are completed, and when we have the final report on them,” says Mikael Lindstam, Aptahem CEO.
The entire toxicology programme consists of two different phases of trials: non-GLP and GLP. Currently, it is difficult to estimate the amount of time the trials will take because several factors are involved, and evaluation periods of such trials typically have uncertain timelines. The results will be announced by the company as soon as the final report has been obtained for each phase of the study.
For further information:
Mikael Lindstam, CEO, Aptahem AB
Tel: + 46 (0)766-33 36 99
This information is information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 15th of May 2018.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.